There are limited case reports of thymoma associated paraneoplastic encephalitis (TAPE) involving inflammation of the limbic or extralimbic areas of the brain, which can potentially lead to ...

Case A 79 year old man with a background of hypertension presented with subacute onset of ataxia, oscillopsia as result of downbeat nystagmus and dysarthria. On examination he was areflexic. MRI brain ...

Ataxia and apraxia can both occur due to conditions that cause lesions on the brain, including tumors, brain injuries, and serious neurological disorders, such as multiple sclerosis.

Session ID: 2025-07-06:b986439bec7b0f52264fbce7 Player Element ID: V35f32f2f_f77f_4abf_831a_588ce1e862ee_6374134131112 ...

Nearly three decades after the final episode of his beloved TV show aired, Bill Nye the Science Guy is still advocating for science. In fact, in an era when science often feels under siege, he’s ...

Company News Published 06/23/2025, 07:05 AM 0 Larimar plans BLA submission for Friedreich’s ataxia drug in 2026 LRMR 7.81% ...

“Recognizing the symptoms of Friedreich ataxia typically begin in childhood, and earlier onset of symptoms is associated with faster disease progression, there is tremendous unmet need in the ...

Biogen Inc, a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for communities, announced the initiation of ...

Alexis Baker, living with Friedreich's Ataxia, shares her journey of perseverance, career success, and advocacy while navigating life in her 20s.

Biogen Inc. has launched the BRAVE study, a global Phase 3 clinical trial aimed at assessing the efficacy and safety of omaveloxolone in children aged 2 to under 16 years with Friedreich ataxia ...

Global Phase 3 BRAVE study will evaluate the efficacy and safety of omaveloxolone in children 2 to <16 years old with Friedreich ataxia, a rare neurodegenerative disorder BRAVE study will explore the ...

It has begun dosing in the global Phase 3 BRAVE trial to test omaveloxolone (SKYCLARYS®) in children aged 2 to 16 with Friedreich ataxia (FA), a rare neurological illness.